Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Sep;41(9):1944–1948. doi: 10.1128/aac.41.9.1944

Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.

T J Walsh 1, P Whitcomb 1, S Piscitelli 1, W D Figg 1, S Hill 1, S J Chanock 1, P Jarosinski 1, R Gupta 1, P A Pizzo 1
PMCID: PMC164041  PMID: 9303390

Abstract

The safety, tolerance, and pharmacokinetics of amphotericin B lipid complex (ABLC) were studied in a cohort of pediatric cancer patients. Six children with hepatosplenic candidiasis (HSC) received 2.5 mg of ABLC/kg of body weight/day for 6 weeks for a total dosage of 105 mg/kg. Mean serum creatinine (0.85 +/- 0.12 mg/dl at baseline) was stable at the end of therapy at 0.85 +/- 0.18 mg/dl and at 1-month follow-up at 0.72 +/- 0.12 mg/dl. There was no increase in hepatic transaminases. Mean plasma concentrations over the dosing interval (C(ave)) and area under the curve from 0 to 24 h (AUC(0-24h)) increased between the first and seventh doses but were similar between doses 7 and 42, suggesting that steady state was achieved by day 7 of therapy. Following the final (42nd) dose of ABLC, mean AUC(0-24h) was 11.9 +/- 2.6 microg h/ml, C(ave) was 0.50 +/- 0.11 microg/ml, maximum concentration of the drug in whole blood was 1.69 +/- 0.75 microg/ml, and clearance was 3.64 +/- 0.78 ml/min/kg. Response of hepatic and splenic lesions was monitored by serial computerized tomographic and magnetic resonance imaging scans. The five evaluable patients responded to ABLC with complete or partial resolution of physical findings and of lesions of HSC. During the course of ABLC infusions and follow-up, there was no progression of HSC, breakthrough fungemia, or posttherapy recurrence. Hepatic lesions continued to resolve after the completion of administration of ABLC. Thus, ABLC administered in multiple doses to children was safe, was characterized by a steady state attainable within 1 week of therapy, and was effective in treatment of HSC.

Full Text

The Full Text of this article is available as a PDF (192.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anaissie E., Bodey G. P., Kantarjian H., David C., Barnett K., Bow E., Defelice R., Downs N., File T., Karam G. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med. 1991 Aug;91(2):142–150. doi: 10.1016/0002-9343(91)90006-j. [DOI] [PubMed] [Google Scholar]
  2. Benson J. M., Nahata M. C. Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother. 1989 Nov;33(11):1989–1993. doi: 10.1128/aac.33.11.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Evans T. G., Mayer J., Cohen S., Classen D., Carroll K. Fluconazole failure in the treatment of invasive mycoses. J Infect Dis. 1991 Dec;164(6):1232–1235. doi: 10.1093/infdis/164.6.1232. [DOI] [PubMed] [Google Scholar]
  4. Flynn P. M., Marina N. M., Rivera G. K., Hughes W. T. Candida tropicalis infections in children with leukemia. Leuk Lymphoma. 1993 Jul;10(4-5):369–376. doi: 10.3109/10428199309148562. [DOI] [PubMed] [Google Scholar]
  5. Hiemenz J. W., Walsh T. J. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis. 1996 May;22 (Suppl 2):S133–S144. doi: 10.1093/clinids/22.supplement_2.s133. [DOI] [PubMed] [Google Scholar]
  6. Janoff A. S., Boni L. T., Popescu M. C., Minchey S. R., Cullis P. R., Madden T. D., Taraschi T., Gruner S. M., Shyamsunder E., Tate M. W. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci U S A. 1988 Aug;85(16):6122–6126. doi: 10.1073/pnas.85.16.6122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kan V. L., Bennett J. E., Amantea M. A., Smolskis M. C., McManus E., Grasela D. M., Sherman J. W. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J Infect Dis. 1991 Aug;164(2):418–421. doi: 10.1093/infdis/164.2.418. [DOI] [PubMed] [Google Scholar]
  8. Kauffman C. A., Bradley S. F., Ross S. C., Weber D. R. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med. 1991 Aug;91(2):137–141. doi: 10.1016/0002-9343(91)90005-i. [DOI] [PubMed] [Google Scholar]
  9. Koren G., Lau A., Klein J., Golas C., Bologa-Campeanu M., Soldin S., MacLeod S. M., Prober C. Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr. 1988 Sep;113(3):559–563. doi: 10.1016/s0022-3476(88)80653-x. [DOI] [PubMed] [Google Scholar]
  10. Levine S. J., Walsh T. J., Martinez A., Eichacker P. Q., Lopez-Berestein G., Natanson C. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med. 1991 Apr 15;114(8):664–666. doi: 10.7326/0003-4819-114-8-664. [DOI] [PubMed] [Google Scholar]
  11. Lopez-Berestein G., Bodey G. P., Frankel L. S., Mehta K. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol. 1987 Feb;5(2):310–317. doi: 10.1200/JCO.1987.5.2.310. [DOI] [PubMed] [Google Scholar]
  12. Miller J. H., Greenfield L. D., Wald B. R. Candidiasis of the liver and spleen in childhood. Radiology. 1982 Feb;142(2):375–380. doi: 10.1148/radiology.142.2.6948317. [DOI] [PubMed] [Google Scholar]
  13. Perkins W. R., Minchey S. R., Boni L. T., Swenson C. E., Popescu M. C., Pasternack R. F., Janoff A. S. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta. 1992 Jun 30;1107(2):271–282. doi: 10.1016/0005-2736(92)90414-h. [DOI] [PubMed] [Google Scholar]
  14. Ringdén O., Tollemar J. Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections in immunocompromised children. Mycoses. 1993 May-Jun;36(5-6):187–192. doi: 10.1111/j.1439-0507.1993.tb00748.x. [DOI] [PubMed] [Google Scholar]
  15. Starke J. R., Mason E. O., Jr, Kramer W. G., Kaplan S. L. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis. 1987 Apr;155(4):766–774. doi: 10.1093/infdis/155.4.766. [DOI] [PubMed] [Google Scholar]
  16. Tashjian L. S., Abramson J. S., Peacock J. E., Jr Focal hepatic candidiasis: a distinct clinical variant of candidiasis in immunocompromised patients. Rev Infect Dis. 1984 Sep-Oct;6(5):689–703. doi: 10.1093/clinids/6.5.689. [DOI] [PubMed] [Google Scholar]
  17. Thaler M., Pastakia B., Shawker T. H., O'Leary T., Pizzo P. A. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med. 1988 Jan;108(1):88–100. doi: 10.7326/0003-4819-108-1-88. [DOI] [PubMed] [Google Scholar]
  18. Walsh T. J., Garrett K., Feurerstein E., Girton M., Allende M., Bacher J., Francesconi A., Schaufele R., Pizzo P. A. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother. 1995 May;39(5):1065–1069. doi: 10.1128/aac.39.5.1065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Walsh T. J., Gonzalez C., Lyman C. A., Chanock S. J., Pizzo P. A. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv Pediatr Infect Dis. 1996;11:187–290. [PubMed] [Google Scholar]
  20. Walsh T. J., Whitcomb P. O., Revankar S. G., Pizzo P. A. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer. 1995 Dec 1;76(11):2357–2362. doi: 10.1002/1097-0142(19951201)76:11<2357::aid-cncr2820761126>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  21. Wiley J. M., Smith N., Leventhal B. G., Graham M. L., Strauss L. C., Hurwitz C. A., Modlin J., Mellits D., Baumgardner R., Corden B. J. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol. 1990 Feb;8(2):280–286. doi: 10.1200/JCO.1990.8.2.280. [DOI] [PubMed] [Google Scholar]
  22. von Eiff M., Fahrenkamp A., Roos N., Fegeler W., van de Loo J. Hepatosplenic candidosis--a late manifestation of Candida septicemia. Mycoses. 1990 Jun;33(6):283–290. doi: 10.1111/myc.1990.33.6.283. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES